Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580873 | 0.87 | ALDH1A1 (0.60) | MAPTNPSR1ALDH1A1TDP1LMNA | |
| SCHEMBL1342267 | 0.87 | MAPT (0.55) | MAPTNPSR1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL8076951 | 0.86 | L3MBTL1 (0.62) | HTTL3MBTL1RAB9AALDH1A1TDP1 | |
| SCHEMBL4637188 | 0.86 | TDP1 (0.58) | MAPTNPSR1HTTL3MBTL1ALDH1A1 | |
| SCHEMBL8077126 | 0.86 | MAPT (0.48) | MAPTNPSR1HTTL3MBTL1ALDH1A1 | |
| SCHEMBL25666679 | 0.85 | MAPT (0.49) | MAPTNPSR1HTTL3MBTL1NPC1 | |
| SCHEMBL4579614 | 0.85 | TTR (0.57) | MAPTNPSR1ALDH1A1TDP1LMNA | |
| SCHEMBL26758686 | 0.85 | ALDH1A1 (0.53) | MAPTNPSR1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL25666684 | 0.84 | MAPT (0.48) | MAPTNPSR1HTTL3MBTL1NPC1 | |
| SCHEMBL4003993 | 0.83 | ALDH1A1 (0.56) | MAPTNPSR1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-0799198-B1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0799198-A4 | — | — | 1997-10-15 | — | — | EP | disclosed |
| EP-0799198-A1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5545669-A | Anti-inflammatory compounds | SMITHKLINE BEECHAM CORPORATION | 1996-08-13 | — | — | US | disclosed |
| WO-1995033461-A1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | MAPT 151/4885NPSR1 1263/4885HSP90AA1 698/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | MAPT 151/4885NPSR1 1263/4885HSP90AA1 698/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | MAPT 3745/4885NPSR1 2599/4885HSP90AA1 929/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | MAPT 2978/4885NPSR1 3653/4885HSP90AA1 1690/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | MAPT 3745/4885NPSR1 2599/4885HSP90AA1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.